Background: The aim of this research was to observe changes in IGF-I and steroid hormones in postmenopausal women with benign and malignant ovarian tumors.
Material And Methods: The concentrations of insulin-like growth factor I (IGF-I), 17-b-estradiol and progesterone were examined by radioimmunological assay in three groups of postmenopausal women: patients with malignant ovarian tumors, patients with benign ovarian tumors, and healthy women. In all three groups the age and body mass index (BMI) were comparable.
Results: The concentrations of IGF-I in the serum of the patients with malignant cancer were significantly lower. The concentrations of estradiol were significantly higher in the patients with both benign and malignant ovarian tumors as compared to the controls.
Conclusions: Decreased IGF-I concentration in the serum of postmenopausal women with ovarian tumors may suggest that the tumor is malignant.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Characterization of Human Senescent Cell Biomarkers for Clinical Trials.
Aging Cell
January 2025
Division of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
There is an increasing need for biomarkers of senescent cell burden to facilitate the selection of participants for clinical trials. p16 is encoded by the CDKN2A locus, which produces five variant transcripts in humans, two of which encode homologous p16 proteins: p16, encoded by p16_variant 1, and p16ɣ, encoded by p16_variant 5. While distinct quantitative polymerase chain reaction primers can be designed for p16_variant 5, primers for p16_variant 1 also measure p16_variant 5 (p16_variant 1 + 5).
View Article and Find Full Text PDFLong-term recurrence after parathyroidectomy in primary hyperparathyroidism-do predictors exist?
Gland Surg
December 2024
Department of General, Visceral, Thoracic, Vascular and Transplant Surgery, University Medical Center Rostock, Rostock, Germany.
Background: Primary hyperparathyroidism (pHPT) is the third most common endocrine disease, affecting predominantly postmenopausal women. About 85% of cases are caused by a solitary parathyroid adenoma which leads to a hypersecretion of the parathyroid hormone (PTH) and consequently to elevated serum calcium concentrations. Parathyroidectomy is the only curative treatment.
View Article and Find Full Text PDFRANK/RANKL Signaling Pathway in Breast Development and Cancer.
Adv Exp Med Biol
January 2025
Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
RANK pathway has attracted increasing interest as a promising target in breast cancer, given the availability of denosumab, an anti-RANKL drug. RANK signaling mediates progesterone-driven regulation of mammary gland development and favors breast cancer initiation by controlling mammary cell proliferation and stem cell fate. RANK activation promotes luminal mammary epithelial cell senescence, acting as an initial barrier to tumorigenesis but ultimately facilitating tumor progression and metastasis.
View Article and Find Full Text PDFElacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial.
Clin Cancer Res
January 2025
Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Introduction: Elacestrant has shown significantly prolonged progression-free survival compared to standard-of-care endocrine therapy in estrogen receptor-positive (ER-positive), HER2-negative metastatic breast cancer (BC), while potential benefit in early-stage disease requires further exploration. The SOLTI-ELIPSE window-of-opportunity trial investigated the biological changes induced by a short course of preoperative elacestrant in postmenopausal women with early BC.
Methods: Eligible patients with untreated T1c (≥1.
Sleep disturbance and menopause.
Curr Opin Obstet Gynecol
January 2025
Department of Obstetrics & Gynecology, Stanford University, Stanford, California, USA.
Purpose Of Review: Sleep problems are among the most prevalent and bothersome symptoms of menopause. This review characterizes menopausal sleep disturbances, describes biopsychosocial predictors, and summarizes the evidence supporting pharmacological and nonpharmacological treatment options.
Recent Findings: Recent studies found that sleep changes are early indicators of perimenopause and sought to disentangle the respective impacts of menopausal status, hot flashes (HFs), and changes in reproductive hormones on peri-/postmenopausal sleep problems.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!